Otozomal Dominant Polikistik Böbrek Hastalarında Arteriyel Sertlik ile s-Klotho ve FGF23 Düzeyleri Arasındaki İlişki

Yıl 2017, Cilt: 3 Sayı: 2, 89 - 94, 01.01.2017

Ayça İnci Funda Sarı Metin Sarıkaya Necat Yılmaz

Öz

Amaç: Bu kesitsel çalışmada; Otozomal Dominant Polikistik Böbrek hastalarında soluble Klotho, FGF23 düzeyleri ile arteriyel sertlik arasındaki ilişki incelenmiştir. Gereç ve Yöntemler: Otozomal Dominant Polikistik Böbrek Hastalığı ODPBH tanısı olan 74 hasta ortalama yaş:50,92±15,70 yıl ve 32 sağlıklı kontol ortalama yaş:49,53±7,32 yıl çalışmaya alınmıştır. Kan örnekleri soluble Klotho, FGF23, serum kreatinin, Kalsiyum, Fosfor ve Parathormon ölçümleri için toplanmıştır. Brakial arter nabız dalga hızı ve kan basıncı aynı monitör kullanılarak ölçülmüştür. Bulgular: Soluble Klotho, FGF23 ve Parathormon düzeyleri hastalarda kontrol grubuna göre anlamlı yüksek saptanmıştır p

Anahtar Kelimeler

Soluble klotho, FGF23, Arteriyel sertlik, Polikistik böbrek hastalığı

Relationship Between Arterial Stiffness and s-Klotho, FGF23 Levels in Autosomal Dominant Polycystic Kidney Disease Patients

Öz

Objective: In this cross-sectional study, we investigated the relationship between soluble Klotho levels, FGF23 levels and arterial stiffness in Autosomal Dominant Polycystic Kidney Disease patients.Material and Methods: 74 patients mean age: 50.92 ± 15.70 years with autosomal Dominant Polycystic Kidney Disease and 32 healthy controls mean age: 49.53 ± 7.32 years were included in the study. Blood samples were collected to measure the levels of soluble Klotho, FGF23, serum creatinine, Calcium, Phosphorus and parathyroid hormone. Brachial artery pulse wave velocity and blood pressure were also measured using a combined monitor.Results: Soluble Klotho, FGF23 and parathyroid hormone levels were significantly higher in the patients than in controls p

Anahtar Kelimeler

Soluble klotho, FGF23, Arterial stiffness, Polycystic renal disease

Kaynakça

• Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D. Polycystic kidney disease re-evaluated: A population-based study. Q J Med 1991;79(290):477-85.
• Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med. 1993;329(5):332-42.
• Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-1301.
• Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009;5:221-8.
• Masoumi A, Elhassan E, Schrier RW. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications. Iran J Kidney Dis 2011;5:1-8.
• Wang Y, Sun Z. Current understanding of Klotho. Ageing Res Rev 2009; 8: 43-51.
• Komaba H, Fukagawa M. The role of FGF23 in CKD- with or without Klotho. Nat Rev Nephrol 2012; 8: 484-90.
• Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A, Yamanari T, Kikumoto Y, Uchida HA, Kitamura S, Maeshima Y, Nakamura K, Ito H, Makino H. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8: e56695.
• Covic A, Florea L, Gusbeth-Tatomir P, Goldsmith DJ. Arteriall stiffness in renal patients: An update. AJKD 2005; 45(6): 965–77.
• Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205:385-90.
• DeLoach SS, Townsend RR: Vascular stiffness: Its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol 2008; 3 (1): 184-92.
• Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
• Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H, Emoto M, Nishizawa Y. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17: 658-65.
• Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-55.
• Hu MC, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-36.
• Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, Matsumura Y, Masuda H, Kurabayashi M, Kuro-o M, Nabeshima Y, Nagai R. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998; 248: 324-9.
• Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL. Soluble Klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012;7:248-57.
• Sari F, Inci A, Dolu S, Ellidag HY, Cetinkaya R, Ersoy FF. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease. J Investig Med 2016;65(2):358-62.
• Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-408.
• Yildiz A, Gul CB, Ersoy A, Asiltas B, Ermurat S, Dogan S, Karaagac K, Sag S, Oruc A, Aktas N, Ocakoglu G, Dogan I, Gullulu S, Gullulu M. Arterial Dysfunction in Early Autosomal Dominant Polycystic Kidney Disease Independent of Fibroblast Growth Factor 23.Iranian Journal of Kidney Diseases; Tehran 8.6. 2014: 443-9.